ASCO Annual Meeting
Annual Meeting of American Society of Clinical Oncology (ASCO)
Chicago, June 3 - June 7, 2011
Investor Updates
- Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations read more
- Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer read more
- Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse read more
- Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO read more
- MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse read more
- Roche Analyst Event at ASCO 2011 read more
More Information
Webcast replay
Analyst briefing on data presented at ASCO: Sunday, June 5
Highlights:
- Vemurafenib in advanced melanoma, BRIM3 study
Antoni Ribas, MD, PhD, Associate Professor, Department of Medicine,
Division of Hematology/Oncology, University of California Los Angeles (UCLA) School of Medicine - Oncology pipeline update
Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development - Avastin in relapsed ovarian cancer, OCEANS study
Jakob Dupont, M.D., Global Medical Director, Avastin - Moving the standard of care through PHC – new opportunities for Roche
Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals